News
How AI speech analysis could predict dementia onset

AI could be used to predict whether a person will develop Alzheimer’s-associated dementia by simply analysing their speech, scientists believe.
Researchers at Boston University are exploring how analysis of speech patterns via a machine learning model could detect with a high degree of accuracy whether someone with mild cognitive impairment will develop Alzheimer’s-associated dementia within six years
They say their model can predict, with an accuracy rate of 78.5 percent, whether someone with mild cognitive impairment is likely to remain stable over the next six years—or fall into the dementia associated with Alzheimer’s disease.
While allowing clinicians to make earlier diagnoses, the researchers say their work could also help make cognitive impairment screening more accessible by automating parts of the process; with no expensive lab tests, imaging exams, or office visits required.
Ioannis (Yannis) Paschalidis, director of the Boston University Rafik B. Hariri Institute for Computing and Computational Science & Engineering, says: “We wanted to predict what would happen in the next six years—and we found we can reasonably make that prediction with relatively good confidence and accuracy.
“We hope, as everyone does, that there will be more and more Alzheimer’s treatments made available.
“If you can predict what will happen, you have more of an opportunity and time window to intervene with drugs, and at least try to maintain the stability of the condition and prevent the transition to more severe forms of dementia.”
The project involves a multidisciplinary team of engineers, neurobiologists, and computer and data scientists.
“We hope, as everyone does, that there will be more and more Alzheimer’s treatments made available,” says Paschalidis.
“If you can predict what will happen, you have more of an opportunity and time window to intervene with drugs, and at least try to maintain the stability of the condition and prevent the transition to more severe forms of dementia.”
To train and build their new model, the researchers turned to data from one of the oldest and longest-running studies in the US —the BU-led Framingham Heart Study.
Although the Framingham study is focused on cardiovascular health, participants showing signs of cognitive decline undergo regular neuropsychological tests and interviews, producing a wealth of longitudinal information on their cognitive well-being.
Paschalidis and his colleagues were given audio recordings of 166 initial interviews with people, between ages 63 and 97, diagnosed with mild cognitive impairment—76 who would remain stable for the next six years and 90 whose cognitive function would progressively decline.
They then used a combination of speech recognition tools—similar to the programs powering your smart speaker—and machine learning to train a model to spot connections between speech, demographics, diagnosis, and disease progression.
After training it on a subset of the study population, they tested its predictive prowess on the rest of the participants.
“We combine the information we extract from the audio recordings with some very basic demographics—age, gender, and so on—and we get the final score,” says Paschalidis. “You can think of the score as the likelihood, the probability, that someone will remain stable or transition to dementia. It had significant predictive ability.”
Rather than using acoustic features of speech, like enunciation or speed, the model is just pulling from the content of the interview—the words spoken, how they’re structured.
And Paschalidis says the information they put into the machine learning program is rough around the edges: the recordings, for example, are messy—low-quality and filled with background noise.
“It’s a very casual recording,” he says. “And still, with this dirty data, the model is able to make something out of it.”
That’s important, because the project was partly about testing AI’s ability to make the process of dementia diagnosis more efficient and automated, with little human involvement.
In the future, the researchers say, models like theirs could be used to bring care to patients who aren’t near medical centers or to provide routine monitoring through interaction with an at-home app, drastically increasing the number of people who get screened.
According to Alzheimer’s Disease International, the majority of people with dementia worldwide never receive a formal diagnosis, leaving them shut off from treatment and care.
Rhoda Au, a coauthor on the paper, says AI has the power to create “equal opportunity science and healthcare.”
The study builds on the same team’s previous work, where they found AI could accurately detect cognitive impairment using voice recordings.
In future research, Paschalidis would like to explore using data not just from formal clinician-patient interviews—with their scripted questions and predictable back-and-forth—but also from more natural, everyday conversations.
He’s already looking ahead to a project on if AI can help diagnose dementia via a smartphone app, as well as expanding the current study beyond speech analysis—the Framingham tests also include patient drawings and data on daily life patterns—to boost the model’s predictive accuracy.
“Digital is the new blood,” says Au. “You can collect it, analyse it for what is known today, store it, and reanalyse it for whatever new emerges tomorrow.”
News
Gut-friendly foods may damage heart, charity warns
News
Diabetes patients face increased risk of undiagnosed heart failure

People with diabetes may have undiagnosed heart failure that could be detected by a simple screening blood test, research suggests.
The TARTAN-HF trial found that one in four patients with diabetes who had at least one other risk factor for heart failure had undiagnosed heart failure detected through screening with a blood test and ultrasound scanning of the heart.
Experts said the findings show the extent of unrecognised heart failure in people with diabetes, and how the condition can be detected using a widely available blood test called NT-proBNP, which measures how much strain the heart is under.
They suggest a heart failure screening programme for diabetics could improve diagnosis rates, lead to earlier treatment and potentially reduce the risk of hospitalisation and death.
The study, involving 700 patients, was led by the University of Glasgow in collaboration with AstraZeneca, Roche Diagnostics, Us2.ai, NHS Greater Glasgow and Clyde and NHS Lanarkshire.
Dr Kieran Docherty, clinical senior lecturer at the University of Glasgow’s School of Cardiovascular and Metabolic Health, said: “Our results from the landmark TARTAN-HF trial identified heart failure in a large proportion of people living with diabetes, emphasising the need for a heart failure screening strategy in this group of patients.
“We know that many of the symptoms and signs of heart failure are non-specific, and may go unrecognised as potentially being due to heart failure for a long time.
“The strategy used in our trial is simple and easy to implement in clinical practice, and will aid in the early identification of heart failure in people with diabetes, and facilitate the initiation of medications that we know improve outcomes in patients with heart failure.”
The study, which began more than three years ago, involved more than 700 people with diabetes from the two health board areas who had at least one other risk factor for heart failure.
They were randomly assigned either to receive heart failure screening or to continue with their usual care.
Researchers found screening uncovered a large number of previously unrecognised cases of heart failure. Around one in four, or 24.9 per cent, of those screened were found to have the condition within six months, compared with 1 per cent in the group continuing their usual care.
The study, involving patients with type 1 and type 2 diabetes, found almost all of the participants found to have heart failure had preserved ejection fraction, which can be difficult to detect without dedicated testing.
The findings of the TARTAN-HF trial were presented at the American College of Cardiology conference taking place from 28 to 30 March in New Orleans in the US.
Dr Edward Piper, medical director at AstraZeneca UK, said: “Delayed diagnosis and treatment of heart failure in people with type 2 diabetes contributes to poor long-term outcomes. TARTAN-HF demonstrates that targeted, risk-based screening can identify previously undiagnosed heart failure in approximately one in four high-risk patients with diabetes, enabling earlier intervention with guideline-directed therapy.”
Dr Christian Simon, head of global medical affairs at Roche Diagnostics, said: “We are proud to have supported the landmark TARTAN-HF trial. These findings demonstrate the transformative power of early, accessible diagnostics like the NT-proBNP blood test.
“By identifying unrecognised heart failure in people with diabetes, we enable clinicians to initiate appropriate treatments sooner, ultimately improving patient outcomes and lives.”
News
UK government announces £6.3m fund to boost men’s health

The UK has launched a £6.3m men’s health fund to back local projects aimed at helping men and boys live longer, healthier lives.
The Men’s Health Community Fund is a partnership between the Department of Health and Social Care, Movember and People’s Health Trust.
The government is contributing £3m, while the two charities are more than doubling that to take the total to £6.3m.
Grants will support community projects reaching underserved men and boys aged 16 and over, particularly in the most disadvantaged areas and at key points in their lives such as becoming a father, losing a job or retiring.
Projects could include support for new fathers, activities for men facing loneliness and social isolation, services to help young men engage with the health system, and support for men in work, out of work and moving into retirement.
The programme will bring together voluntary, community and social enterprise organisations to test new ways of reaching men who are least likely to use traditional health services.
An evaluation funded through the National Institute for Health and Care Research will assess what works and help inform future policy and delivery.
Health and social care secretary Wes Streeting said: “Too many men across the country are living shorter, less healthy lives, particularly those in our most disadvantaged communities.
“This new partnership will help men get the support they need in the places they feel most comfortable, their communities, among people they trust.
“By working with expert charities and local organisations, we can reach the men who are too often missed by traditional services and help them take better care of their mental and physical health.”
“It is a key step in delivering our first ever Men’s Health Strategy and driving forward our ambition to halve the gap in healthy life expectancy between the richest and poorest areas.”
The Men’s Health Strategy sets out plans to tackle the physical and mental health challenges men and boys face.
Men can be less likely to seek help and more likely to suffer in silence, while higher rates of smoking, drinking, gambling and drug use are damaging men’s health and affecting families, workplaces and communities.
The government is also investing £3.6m over the next three years in suicide prevention projects for middle-aged men in local communities across areas of England where men are most at risk, many of which are also among the most deprived. Suicide is one of the biggest killers of men under 50, and three-quarters of all suicides are men.
The projects will aim to break down barriers middle-aged men face in seeking support, including stigma around asking for help and a lack of awareness of what is available and how to access it.
They will be co-designed with experts and men with lived experience of mental health crises and suicidal thoughts.








